Purinergic signaling pathway enzyme (None commonly standardized; individual enzymes may have their own abbreviations, e.g., CD39, CD73.)

Enzymes of the purinergic signaling pathway, predominantly ectonucleotidases such as E-NTPDase1 (CD39) and ecto-5'-nucleotidase (CD73), play a central role in cell-cell communication by regulating the extracellular concentrations of purine and pyrimidine nucleotides, especially ATP, ADP, AMP, and adenosine. These enzymes hydrolyze ATP and ADP to AMP and further AMP to adenosine, modulating activation of P2 and P1 purinergic receptors. Their activity impacts a wide spectrum of biological processes including neurotransmission, immune modulation, inflammation, and signaling in cancer and neurodegenerative disease. Targeting these enzymes is a promising therapeutic strategy, but the pathway includes a variety of related and interacting enzymes, each with potentially specific roles and associated drugs[1][5][6]. Note: For structured data and unambiguous linking, it is advisable to create distinct entries per individual enzyme (e.g., E-NTPDase1 [CD39], ecto-5'-nucleotidase [CD73]), rather than grouping them as “Purinergic signaling pathway enzymes.”

Other names

Purinergic enzymesectonucleotidasesE-NTPDasesCD39 (for E-NTPDase1)CD73 (for ecto-5'-nucleotidase)

Enzyme inhibition: prevents hydrolysis of ATP/ADP/AMP, altering extracellular nucleotide/nucleoside balance; Modulation of immune cell signaling (e.g., altering adenosine-mediated immunosuppression); Enhancement of anti-tumor immune response via blockade of adenosine pathway